References
Key articles
National Institutes of Health; National Heart, Lung, and Blood Institute, National Asthma Education and Prevention Program. Expert panel report 3: Guidelines for the diagnosis and management of asthma. August 2007 [internet publication].Full text
Global Initiative for Asthma. 2024 global strategy for asthma management and prevention. May 2024 [internet publication].Full text
Expert Panel Working Group of the National Heart, Lung, and Blood Institute (NHLBI) administered and coordinated National Asthma Education and Prevention Program Coordinating Committee (NAEPPCC); Cloutier MM, Baptist AP, Blake KV, et al. 2020 focused updates to the asthma management guidelines: a report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group. J Allergy Clin Immunol. 2020 Dec;146(6):1217-70.Full text Abstract
National Institute for Health and Care Excellence. Asthma: diagnosis, monitoring and chronic asthma management. March 2021 [internet publication].Full text
British Thoracic Society; Scottish Intercollegiate Guidelines Network. British guideline on the management of asthma: a national clinical guideline. July 2019 [internet publication].Full text
Reference articles
1. National Institutes of Health; National Heart, Lung, and Blood Institute, National Asthma Education and Prevention Program. Expert panel report 3: Guidelines for the diagnosis and management of asthma. August 2007 [internet publication].Full text
2. Weiler JM, Brannan JD, Randolph CC, et al. Exercise-induced bronchoconstriction update: 2016. J Allergy Clin Immunol. 2016 Nov;138(5):1292-5.Full text Abstract
3. Centers for Disease Control and Prevention. Most recent national asthma data. May 2023 [internet publication].Full text
4. Centers for Disease Control and Prevention. Asthma as the underlying cause of death. Jul 2023 [internet publication].Full text
5. To T, Stanojevic S, Moores G, et al. Global asthma prevalence in adults: findings from the cross-sectional world health survey. BMC Public Health. 2012 Mar 19;12:204.Full text Abstract
6. Global Asthma Network. The global asthma report 2018 [internet publication].Full text
7. Masoli M, Fabian D, Holt S, et al; Global Initiative for Asthma (GINA) Program. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy. 2004 May;59(5):469-78.Full text Abstract
8. Singh AM, Busse WW. Asthma exacerbations. 2: aetiology. Thorax. 2006 Sep;61(9):809-16.Full text Abstract
9. Wark PA, Gibson PG. Asthma exacerbations. 3: pathogenesis. Thorax. 2006 Oct;61(10):909-15.Full text Abstract
10. Shapiro SD, Owen CA. ADAM-33 surfaces as an asthma gene. N Engl J Med. 2002 Sep 19;347(12):936-8. Abstract
11. Makoui MH, Imani D, Motallebnezhad M, et al. Vitamin D receptor gene polymorphism and susceptibility to asthma: meta-analysis based on 17 case-control studies. Ann Allergy Asthma Immunol. 2020 Jan;124(1):57-69. Abstract
12. El-Husseini ZW, Gosens R, Dekker F, et al. The genetics of asthma and the promise of genomics-guided drug target discovery. Lancet Respir Med. 2020 Oct;8(10):1045-56. Abstract
13. Ntontsi P, Photiades A, Zervas E, et al. Genetics and epigenetics in asthma. Int J Mol Sci. 2021 Feb 27;22(5):2412.Full text Abstract
14. Restori KH, Srinivasa BT, Ward BJ, et al. Neonatal immunity, respiratory virus infections, and the development of asthma. Front Immunol. 2018;9:1249.Full text Abstract
15. Pietinalho A, Pelkonen A, Rytilä P. Linkage between smoking and asthma. Allergy. 2009 Dec;64(12):1722-7.Full text Abstract
16. Ferreira MA, Vonk JM, Baurecht H, et al. Shared genetic origin of asthma, hay fever and eczema elucidates allergic disease biology. Nat Genet. 2017 Dec;49(12):1752-57. Abstract
17. Joshi D, Duong M, Kirkland S, et al. Impact of electronic cigarette ever use on lung function in adults aged 45-85: a cross-sectional analysis from the Canadian Longitudinal Study on Aging. BMJ Open. 2021 Oct 27;11(10):e051519.Full text Abstract
18. Wills TA, Soneji SS, Choi K, et al. E-cigarette use and respiratory disorders: an integrative review of converging evidence from epidemiological and laboratory studies. Eur Respir J. 2021 Jan;57(1):1901815.Full text Abstract
19. Rose JJ, Krishnan-Sarin S, Exil VJ, et al. Cardiopulmonary impact of electronic cigarettes and vaping products: a scientific statement from the American Heart Association. Circulation. 2023 Aug 22;148(8):703-28. Abstract
20. Orellano P, Quaranta N, Reynoso J, et al. Effect of outdoor air pollution on asthma exacerbations in children and adults: systematic review and multilevel meta-analysis. PLoS One. 2017 Mar 20;12(3):e0174050.Full text Abstract
21. Paterson CA, Sharpe RA, Taylor T, et al. Indoor PM2.5, VOCs and asthma outcomes: a systematic review in adults and their home environments. Environ Res. 2021 Nov;202:111631.Full text Abstract
22. Nassikas NJ, McCormack MC, Ewart G, et al. Indoor air sources of outdoor air pollution: health consequences, policy, and recommendations: an official American Thoracic Society workshop report. Ann Am Thorac Soc. 2024 Mar;21(3):365-76.Full text Abstract
23. See KC, Phua J, Lim TK. Trigger factors in asthma and chronic obstructive pulmonary disease: a single-centre cross-sectional study. Singapore Med J. 2016 Oct;57(10):561-5.Full text Abstract
24. Burbank AJ, Hernandez ML, Jefferson A, et al. Environmental justice and allergic disease: a work group report of the AAAAI Environmental Exposure and Respiratory Health Committee and the Diversity, Equity and Inclusion Committee. J Allergy Clin Immunol. 2023 Mar;151(3):656-70.Full text Abstract
25. van der Wiel E, ten Hacken NH, Postma DS, et al. Small-airways dysfunction associates with respiratory symptoms and clinical features of asthma: a systematic review. J Allergy Clin Immunol. 2013 Mar;131(3):646-57. Abstract
26. Saikumar Jayalatha AK, Hesse L, Ketelaar ME, et al. The central role of IL-33/IL-1RL1 pathway in asthma: From pathogenesis to intervention. Pharmacol Ther. 2021 Sep;225:107847.Full text Abstract
27. Ballow M. Biologic immune modifiers: trials and tribulations - are we there yet? J Allergy Clin Immunol. 2006 Dec;118(6):1209-15. Abstract
28. Boyce JA. Asthma 2005-2006: bench to bedside. J Allergy Clin Immunol. 2006 Sep;118(3):582-6. Abstract
29. Cockcroft DW, Davis BE. Mechanisms of airway hyperresponsiveness. J Allergy Clin Immunol. 2006 Sep;118(3):551-9. Abstract
30. Kuruvilla ME, Vanijcharoenkarn K, Shih JA, et al. Epidemiology and risk factors for asthma. Respir Med. 2019 Mar;149:16-22.Full text Abstract
31. Gabryszewski SJ, Hill DA. One march, many paths: insights into allergic march trajectories. Ann Allergy Asthma Immunol. 2021 Sep;127(3):293-300. Abstract
32. Polosa R, Thomson NC. Smoking and asthma: dangerous liaisons. Eur Respir J. 2013 Mar;41(3):716-26.Full text Abstract
33. Di Cicco M, Sepich M, Beni A, et al. How E-cigarettes and vaping can affect asthma in children and adolescents. Curr Opin Allergy Clin Immunol. 2022 Apr 1;22(2):86-94. Abstract
34. Bradford LE, Rebuli ME, Ring BJ, et al. Danger in the vapor? ECMO for adolescents with status asthmaticus after vaping. J Asthma. 2020 Nov;57(11):1168-72. Abstract
35. Feddema JJ, Claassen E. Prevalence of viral respiratory infections amongst asthmatics: Results of a meta-regression analysis. Respir Med. 2020 Nov;173:106020.Full text Abstract
36. Laidlaw TM, Mullol J, Woessner KM, et al. Chronic Rhinosinusitis with Nasal Polyps and Asthma. J Allergy Clin Immunol Pract. 2021 Mar;9(3):1133-1141.Full text Abstract
37. Langdon C, Mullol J. Nasal polyps in patients with asthma: prevalence, impact, and management challenges. J Asthma Allergy. 2016;9:45-53.Full text Abstract
38. Sharma V, Cowan DC. Obesity, inflammation, and severe asthma: an update. Curr Allergy Asthma Rep. 2021 Dec 18;21(12):46.Full text Abstract
39. Miethe S, Karsonova A, Karaulov A, et al. Obesity and asthma. J Allergy Clin Immunol. 2020 Oct;146(4):685-93.Full text Abstract
40. Xu M, Lodge CJ, Lowe AJ, et al. Are adults with asthma less physically active? A systematic review and meta-analysis. J Asthma. 2021 Nov;58(11):1426-43. Abstract
41. Xu S, Gilliland FD, Conti DV. Elucidation of causal direction between asthma and obesity: a bi-directional Mendelian randomization study. Int J Epidemiol. 2019 Jun 1;48(3):899-907.Full text Abstract
42. Asamoah-Boaheng M, Farrell J, Osei Bonsu K, et al. Examining risk factors accelerating time-to-chronic obstructive pulmonary disease (COPD) diagnosis among asthma patients. COPD. 2022;19(1):47-56.Full text Abstract
43. Shore SA. Obesity and asthma: possible mechanisms. J Allergy Clin Immunol. 2008 May;121(5):1087-93. Abstract
44. King GG, Brown NJ, Diba C, et al. The effects of body weight on airway calibre. Eur Respir J. 2005 May;25(5):896-901.Full text Abstract
45. Zhu Z, Guo Y, Shi H, et al. Shared genetic and experimental links between obesity-related traits and asthma subtypes in UK Biobank. J Allergy Clin Immunol. 2020 Feb;145(2):537-49.Full text Abstract
46. Paoletti G, Melone G, Ferri S, et al. Gastroesophageal reflux and asthma: when, how, and why. Curr Opin Allergy Clin Immunol. 2021 Feb 1;21(1):52-58. Abstract
47. Cantarutti A, Barbiellini Amidei C, Valsecchi C, et al. Association of treated and untreated gastroesophageal reflux disease in the first year of life with the subsequent development of asthma. Int J Environ Res Public Health. 2021 Sep 13;18(18):9633. Abstract
48. Rogers L. Role of sleep apnea and gastroesophageal reflux in aevere asthma. Immunol Allergy Clin North Am. 2016 Aug;36(3):461-71. Abstract
49. Kopsaftis Z, Yap HS, Tin KS, et al. Pharmacological and surgical interventions for the treatment of gastro-oesophageal reflux in adults and children with asthma. Cochrane Database Syst Rev. 2021 May 17;5:CD001496.Full text Abstract
50. Prasad B, Nyenhuis SM, Imayama I, et al. Asthma and abstructive sleep apnea overlap: what has the evidence taught us? Am J Respir Crit Care Med. 2020 Jun 1;201(11):1345-57.Full text Abstract
51. Kong DL, Qin Z, Shen H, et al. Association of obstructive sleep apnea with asthma: a meta-analysis. Sci Rep. 2017 Jun 22;7(1):4088.Full text Abstract
52. Global Initiative for Asthma. 2024 global strategy for asthma management and prevention. May 2024 [internet publication].Full text
53. American Academy of Allergy, Asthma & Immunology. Ten things physicians and patients should question. Choosing Wisely, an initiative of the ABIM Foundation. 2021 [internet publication].Full text
54. British Thoracic Society. BTS clinical statement: asssessment and management of respiratory problems in athletic individuals. Apr 2022 [internet publication].Full text
55. Louis R, Satia I, Ojanguren I, et al. European Respiratory Society guidelines for the diagnosis of asthma in adults. Eur Respir J. 2022 Feb 15;2101585 [Epub ahead of print].Full text Abstract
56. British Thoracic Society and Scottish Intercollegiate Guidelines Network. British guideline on the management of asthma. July 2019 [internet publication].Full text
57. Parsons JP, Hallstrand TS, Mastronarde JG, et al. An official American Thoracic Society clinical practice guideline: exercise-induced bronchoconstriction. Am J Respir Crit Care Med. 2013 May 1;187(9):1016-27.Full text Abstract
58. Cockcroft DD. Direct and indirect challenges in the clinical assessment of asthma. Ann Allergy Asthma Immunol. 2009 Nov;103(5):363-9. Abstract
59. Menzies-Gow A, Mansur AH, Brightling CE. Clinical utility of fractional exhaled nitric oxide in severe asthma management. Eur Respir J. 2020 Mar;55(3):1901633.Full text Abstract
60. Expert Panel Working Group of the National Heart, Lung, and Blood Institute (NHLBI) administered and coordinated National Asthma Education and Prevention Program Coordinating Committee (NAEPPCC); Cloutier MM, Baptist AP, Blake KV, et al. 2020 focused updates to the asthma management guidelines: a report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group. J Allergy Clin Immunol. 2020 Dec;146(6):1217-70.Full text Abstract
61. Dweik RA, Boggs PB, Erzurum SC, et al. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. Am J Respir Crit Care Med. 2011 Sep 1;184(5):602-15.Full text Abstract
62. Powell H, Murphy VE, Taylor DR, et al. Management of asthma in pregnancy guided by measurement of fraction of exhaled nitric oxide: a double-blind, randomised controlled trial. Lancet. 2011 Sep 10;378(9795):983-90. Abstract
63. Honkoop PJ, Loijmans RJ, Termeer EH, et al; Asthma Control Cost-Utility Randomized Trial Evaluation (ACCURATE) Study Group. Symptom-and fraction of exhaled nitric oxide-driven strategies for asthma control: a cluster-randomized trial in primary care. J Allergy Clin Immunol. 2015 Mar;135(3):682-8. Abstract
64. Petsky HL, Kew KM, Turner C, et al. Exhaled nitric oxide levels to guide treatment for adults with asthma. Cochrane Database Syst Rev. 2016 Sep 1;(9):CD011440.Full text Abstract
65. Petsky HL, Li A, Chang AB. Tailored interventions based on sputum eosinophils versus clinical symptoms for asthma in children and adults. Cochrane Database Syst Rev. 2017 Aug 24;(8):CD005603.Full text Abstract
66. Khatri SB, Iaccarino JM, Barochia A, et al. Use of fractional exhaled nitric oxide to guide the treatment of asthma: an official American Thoracic Society clinical practice guideline. Am J Respir Crit Care Med. 2021 Nov 15;204(10):e97-e109.Full text Abstract
67. Carden KA, Boiselle PM, Waltz DA, et al. Tracheomalacia and tracheobronchomalacia in children and adults. An in-depth review. Chest. 2005 Mar;127(3):984-1005.Full text Abstract
68. Lee KS, Sun MRM, Ernst A, et al. Comparison of dynamic expiratory CT with bronchoscopy for diagnosing airway malacia: a pilot evaluation. Chest. 2007 Mar;131(3):758-64.Full text Abstract
69. U.S. Food and Drug Administration. Drug safety communication: FDA requires boxed warning about serious mental health side effects for asthma and allergy drug montelukast (Singulair); advises restricting use for allergic rhinitis. March 2020 [internet publication].Full text
70. Mohan A, Lugogo NL, Hanania NA, et al. Questions in mild asthma: an official American Thoracic Society research statement. Am J Respir Crit Care Med. 2023 Jun 1;207(11):e77-96. Abstract
71. Canadian Thoracic Society. Canadian Thoracic Society 2021 guideline update: diagnosis and management of asthma in preschoolers, children and adults. August 2021 [internet publication].Full text
72. Canadian Thoracic Society. Recognition and management of severe asthma: a Canadian Thoracic Society position statement. 2017 [internet publication].Full text
73. Global Initiative for Asthma. Diagnosis and management of difficult-to-treat & severe asthma. 2023 [internet publication].Full text
74. Nakamura Y, Tamaoki J, Nagase H, et al. Japanese guidelines for adult asthma 2020. Allergol Int. 2020 Oct;69(4):519-48.Full text Abstract
75. National Asthma Council. Australian asthma handbook: the national guidelines for health professionals. April 2022 [internet publication].Full text
76. National Institute for Health and Care Excellence. Asthma: diagnosis, monitoring and chronic asthma management. March 2021 [internet publication].Full text
77. British Thoracic Society; Scottish Intercollegiate Guidelines Network. British guideline on the management of asthma: a national clinical guideline. July 2019 [internet publication].Full text
78. Hodkinson A, Bower P, Grigoroglou C, et al. Self-management interventions to reduce healthcare use and improve quality of life among patients with asthma: systematic review and network meta-analysis. BMJ. 2020 Aug 18;370:m2521.Full text Abstract
79. Lazarinis N, Jørgensen L, Ekström T, et al. Combination of budesonide/formoterol on demand improves asthma control by reducing exercise-induced bronchoconstriction. Thorax. 2014 Feb;69(2):130-6.Full text Abstract
80. Ahmad S, Kew KM, Normansell R. Stopping long-acting beta2-agonists (LABA) for adults with asthma well controlled by LABA and inhaled corticosteroids. Cochrane Database Syst Rev. 2015 Jun 19;(6):CD011306.Full text Abstract
81. O'Byrne PM, FitzGerald JM, Bateman ED, et al. Inhaled combined budesonide-formoterol as needed in mild asthma. N Engl J Med. 2018 May 17;378(20):1865-76.Full text Abstract
82. Beasley R, Holliday M, Reddel HK, et al. Controlled trial of budesonide-formoterol as needed for mild asthma. N Engl J Med. 2019 May 23;380(21):2020-30.Full text Abstract
83. Hardy J, Baggott C, Fingleton J, et al. Budesonide-formoterol reliever therapy versus maintenance budesonide plus terbutaline reliever therapy in adults with mild to moderate asthma (PRACTICAL): a 52-week, open-label, multicentre, superiority, randomised controlled trial. Lancet. 2019 Sep 14;394(10202):919-28. Abstract
84. Crossingham I, Turner S, Ramakrishnan S, et al. Combination fixed-dose beta agonist and steroid inhaler as required for adults or children with mild asthma. Cochrane Database Syst Rev. 2021 May 4;(5):CD013518.Full text Abstract
85. O'Byrne PM, FitzGerald JM, Bateman ED, et al. Effect of a single day of increased as-needed budesonide-formoterol use on short-term risk of severe exacerbations in patients with mild asthma: a post-hoc analysis of the SYGMA 1 study. Lancet Respir Med. 2021 Feb;9(2):149-58. Abstract
86. Nwaru BI, Ekström M, Hasvold P, et al. Overuse of short-acting β2-agonists in asthma is associated with increased risk of exacerbation and mortality: a nationwide cohort study of the global SABINA programme. Eur Respir J. 2020 Apr;55(4):1901872.Full text Abstract
87. Papi A, Canonica GW, Maestrelli P, et al. Rescue use of beclomethasone and albuterol in a single inhaler for mild asthma. N Engl J Med. 2007 May 17;356(20):2040-52.Full text Abstract
88. Martinez FD, Chinchilli VM, Morgan WJ, et al. Use of beclomethasone dipropionate as rescue treatment for children with mild persistent asthma (TREXA): a randomised, double-blind, placebo-controlled trial. Lancet. 2011 Feb 19;377(9766):650-7. Abstract
89. Calhoun WJ, Ameredes BT, King TS, et al. Comparison of physician-, biomarker-, and symptom-based strategies for adjustment of inhaled corticosteroid therapy in adults with asthma: the BASALT randomized controlled trial. JAMA. 2012 Sep 12;308(10):987-97.Full text Abstract
90. Sumino K, Bacharier LB, Taylor J, et al. A pragmatic trial of symptom-based inhaled corticosteroid use in African-American children with mild asthma. J Allergy Clin Immunol Pract. 2020 Jan;8(1):176-85.Full text Abstract
91. Stanford RH, Shah MB, D'Souza AO, et al. Short-acting β-agonist use and its ability to predict future asthma-related outcomes. Ann Allergy Asthma Immunol. 2012 Dec;109(6):403-7. Abstract
92. Bloom CI, Cabrera C, Arnetorp S, et al. Asthma-related health outcomes associated with short-acting β2-agonist inhaler use: an observational UK study as part of the SABINA global program. Adv Ther. 2020 Oct;37(10):4190-208.Full text Abstract
93. Amin S, Soliman M, McIvor A, et al. Usage patterns of short-acting β2-agonists and inhaled corticosteroids in asthma: a targeted literature review. J Allergy Clin Immunol Pract. 2020 Sep;8(8):2556-64. Abstract
94. Kaplan AG, Correia-de-Sousa J, McIvor A, et al. Global quality statements on reliever use in asthma in adults and children older than 5 years of age. Adv Ther. 2021 Mar;38(3):1382-96.Full text Abstract
95. Bateman ED, Reddel HK, O'Byrne PM, et al. As-needed budesonide-formoterol versus maintenance budesonide in mild asthma. N Engl J Med. 2018 May 17;378(20):1877-87.Full text Abstract
96. Janjua S, Schmidt S, Ferrer M, et al. Inhaled steroids with and without regular formoterol for asthma: serious adverse events. Cochrane Database Syst Rev. 2019 Sep 25;(9):CD006924.Full text Abstract
97. Chauhan BF, Ducharme FM. Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children. Cochrane Database Syst Rev. 2012 May 16;(5):CD002314.Full text Abstract
98. Ni Chroinin M, Greenstone I, Lasserson TJ, et al. Addition of inhaled long-acting beta2-agonists to inhaled steroids as first line therapy for persistent asthma in steroid-naive adults and children. Cochrane Database Syst Rev. 2009 Oct 7;(4):CD005307.Full text Abstract
99. O'Shea O, Stovold E, Cates CJ. Regular treatment with formoterol and an inhaled corticosteroid versus regular treatment with salmeterol and an inhaled corticosteroid for chronic asthma: serious adverse events. Cochrane Database Syst Rev. 2021 Apr 14;4:CD007694.Full text Abstract
100. Cates CJ, Karner C. Combination formoterol and budesonide as maintenance and reliever therapy versus current best practice (including inhaled steroid maintenance), for chronic asthma in adults and children. Cochrane Database Syst Rev. 2013 Apr 30;(4):CD007313.Full text Abstract
101. Kew KM, Karner C, Mindus SM, et al. Combination formoterol and budesonide as maintenance and reliever therapy versus combination inhaler maintenance for chronic asthma in adults and children. Cochrane Database Syst Rev. 2013 Dec 16;(12):CD009019.Full text Abstract
102. Papi A, Corradi M, Pigeon-Francisco C, et al. Beclometasone-formoterol as maintenance and reliever treatment in patients with asthma: a double-blind, randomised controlled trial. Lancet Respir Med. 2013 Mar;1(1):23-31. Abstract
103. Patel M, Pilcher J, Pritchard A, et al. Efficacy and safety of maintenance and reliever combination budesonide-formoterol inhaler in patients with asthma at risk of severe exacerbations: a randomised controlled trial. Lancet Respir Med. 2013 Mar;1(1):32-42. Abstract
104. Bateman ED, Harrison TW, Quirce S, et al. Overall asthma control achieved with budesonide/formoterol maintenance and reliever therapy for patients on different treatment steps. Respir Res. 2011 Apr 4;12:38.Full text Abstract
105. Jorup C, Lythgoe D, Bisgaard H. Budesonide/formoterol maintenance and reliever therapy in adolescent patients with asthma. Eur Respir J. 2018 Jan;51(1):1701688.Full text Abstract
106. Demoly P, Louis R, Søes-Petersen U, et al. Budesonide/formoterol maintenance and reliever therapy versus conventional best practice. Respir Med. 2009 Nov;103(11):1623-32.Full text Abstract
107. Rogliani P, Ritondo BL, Ora J, et al. SMART and as-needed therapies in mild-to-severe asthma: a network meta-analysis. Eur Respir J. 2020 Sep;56(3):2000625.Full text Abstract
108. Papi A, Chipps BE, Beasley R, et al. Albuterol-budesonide fixed-dose combination rescue inhaler for asthma. N Engl J Med. 2022 Jun 2;386(22):2071-83. Abstract
109. O'Byrne PM, Naya IP, Kallen A, et al. Increasing doses of inhaled corticosteroids compared to adding long-acting inhaled beta2-agonists in achieving asthma control. Chest. 2008 Dec;134(6):1192-9.Full text Abstract
110. Sobieraj DM, Baker WL, Nguyen E, et al. Association of inhaled corticosteroids and long-acting muscarinic antagonists with asthma control in patients with uncontrolled, persistent asthma: a systematic review and meta-analysis. JAMA. 2018 Apr 10;319(14):1473-84.Full text Abstract
111. Kew KM, Dahri K. Long-acting muscarinic antagonists (LAMA) added to combination long-acting beta2-agonists and inhaled corticosteroids (LABA/ICS) versus LABA/ICS for adults with asthma. Cochrane Database Syst Rev. 2016 Jan 21;(1):CD011721.Full text Abstract
112. Kerstjens HAM, Maspero J, Chapman KR, et al. Once-daily, single-inhaler mometasone-indacaterol-glycopyrronium versus mometasone-indacaterol or twice-daily fluticasone-salmeterol in patients with inadequately controlled asthma (IRIDIUM): a randomised, double-blind, controlled phase 3 study. Lancet Respir Med. 2020 Oct;8(10):1000-12. Abstract
113. Kim LHY, Saleh C, Whalen-Browne A, et al. Triple vs dual inhaler therapy and asthma outcomes in moderate to severe asthma: a systematic review and meta-analysis. JAMA. 2021 Jun 22;325(24):2466-79. Abstract
114. Lee LA, Bailes Z, Barnes N, et al. Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial. Lancet Respir Med. 2021 Jan;9(1):69-84. Abstract
115. Virchow JC, Kuna P, Paggiaro P, et al. Single inhaler extrafine triple therapy in uncontrolled asthma (TRIMARAN and TRIGGER): two double-blind, parallel-group, randomised, controlled phase 3 trials. Lancet. 2019 Nov 9;394(10210):1737-49. Abstract
116. Oba Y, Anwer S, Maduke T, et al. Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying doses of inhaled corticosteroids in adolescents and adults with asthma: a systematic review and network meta-analysis. Cochrane Database Syst Rev. 2022 Dec 6;12(12):CD013799.Full text Abstract
117. Hiles SA, McDonald VM, Guilhermino M, et al. Does maintenance azithromycin reduce asthma exacerbations? An individual participant data meta-analysis. Eur Respir J. 2019 Nov;54(5):1901381.Full text Abstract
118. Undela K, Goldsmith L, Kew KM, et al. Macrolides versus placebo for chronic asthma. Cochrane Database Syst Rev. 2021 Nov 22;11:CD002997.Full text Abstract
119. Gibson PG, Yang IA, Upham JW, et al. Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial. Lancet. 2017 Aug 12;390(10095):659-68. Abstract
120. Zaroff JG, Cheetham TC, Palmetto N, et al. Association of azithromycin use with cardiovascular mortality. JAMA Netw Open. 2020 Jun 1;3(6):e208199.Full text Abstract
121. Busby J, Khoo E, Pfeffer PE, et al. The effects of oral corticosteroids on lung function, type-2 biomarkers and patient-reported outcomes in stable asthma: a systematic review and meta-analysis. Respir Med. 2020 Nov;173:106156. Abstract
122. Volmer T, Effenberger T, Trautner C, et al. Consequences of long-term oral corticosteroid therapy and its side-effects in severe asthma in adults: a focused review of the impact data in the literature. Eur Respir J. 2018 Oct;52(4):1800703.Full text Abstract
123. Cataldo D, Louis R, Michils A, et al. Severe asthma: oral corticosteroid alternatives and the need for optimal referral pathways. J Asthma. 2021 Apr;58(4):448-58.Full text Abstract
124. Bardelas J, Figliomeni M, Kianifard F, et al. A 26-week, randomized, double-blind, placebo-controlled, multicenter study to evaluate the effect of omalizumab on asthma control in patients with persistent allergic asthma. J Asthma. 2012 Mar;49(2):144-52. Abstract
125. Hanania NA, Alpan O, Hamilos DL, et al. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial. Ann Intern Med. 2011 May 3;154(9):573-82.Full text Abstract
126. Norman G, Faria R, Paton F, et al. Omalizumab for the treatment of severe persistent allergic asthma: a systematic review and economic evaluation. Health Technol Assess. 2013 Nov;17(52):1-342.Full text Abstract
127. Hambly N, Nair P. Monoclonal antibodies for the treatment of refractory asthma. Curr Opin Pulm Med. 2014 Jan;20(1):87-94. Abstract
128. Laviolette M, Gossage DL, Gauvreau G, et al. Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia. J Allergy Clin Immunol. 2013 Nov;132(5):1086-96. Abstract
129. Wenzel S, Ford L, Pearlman D, et al. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med. 2013 Jun 27;368(26):2455-66.Full text Abstract
130. Menzies-Gow A, Corren J, Bourdin A, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021 May 13;384(19):1800-9. Abstract
131. Wang M, Liu M, Wang C, et al. Association between vitamin D status and asthma control: a meta-analysis of randomized trials. Respir Med. 2019 Apr;150:85-94.Full text Abstract
132. Busse W, Corren J, Lanier BQ, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol. 2001 Aug;108(2):184-90.Full text Abstract
133. Alhossan A, Lee CS, MacDonald K. et al. "Real-life" effectiveness studies of omalizumab in adult patients with severe allergic asthma: meta-analysis. J Allergy Clin Immunol Pract. Sep-Oct 2017;5(5):1362-70. Abstract
134. MacDonald KM, Kavati A, Ortiz B, et al. Short- and long-term real-world effectiveness of omalizumab in severe allergic asthma: systematic review of 42 studies published 2008-2018. Expert Rev Clin Immunol. 2019 May;15(5):553-69.Full text Abstract
135. Faulkner KM, MacDonald K, Abraham I, et al. 'Real-world' effectiveness of omalizumab in adults with severe allergic asthma: a meta-analysis. Expert Rev Clin Immunol. 2021 Jan;17(1):73-83. Abstract
136. Colombo GL, Di Matteo S, Martinotti C, et al. Omalizumab and long-term quality of life outcomes in patients with moderate-to-severe allergic asthma: a systematic review. Ther Adv Respir Dis. 2019 Jan-Dec;13:1753466619841350.Full text Abstract
137. Tourangeau LM, Kavanaugh A, Wasserman SI. The role of monoclonal antibodies in the treatment of severe asthma. Ther Adv Resp Dis. 2011 Jun;5(3):183-94.Full text Abstract
138. Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012 Aug 18;380(9842):651-9. Abstract
139. Liu Y, Zhang S, Li DW, et al. Efficacy of anti-interleukin-5 therapy with mepolizumab in patients with asthma: a meta-analysis of randomized placebo-controlled trials. 2013;8(3):e59872.Full text Abstract
140. Bel EH, Wenzel SE, Thompson PJ, et al; SIRIUS Investigators. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med. 2014 Sep 25;371(13):1189-97.Full text Abstract
141. Ortega HG, Liu MC, Pavord ID, et al; MENSA Investigators. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014 Sep 25;371(13):1198-207.Full text Abstract
142. Albers FC, Papi A, Taillé C, et al. Mepolizumab reduces exacerbations in patients with severe eosinophilic asthma, irrespective of body weight/body mass index: meta-analysis of MENSA and MUSCA. Respir Res. 2019 Jul 30;20(1):169.Full text Abstract
143. Ortega H, Menzies-Gow A, Llanos JP, et al. Rapid and consistent improvements in morning PEF in patients with severe eosinophilic asthma treated with mepolizumab. Adv Ther. 2018 Jul;35(7):1059-68.Full text Abstract
144. Yan K, Balijepalli C, Sharma R, et al. Reslizumab and mepolizumab for moderate-to-severe poorly controlled asthma: an indirect comparison meta-analysis. Immunotherapy. 2019 Dec;11(17):1491-505. Abstract
145. Bleecker ER, FitzGerald JM, Chanez P, et al; SIROCCO Study Investigators. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta-2 agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet. 2016 Oct 29;388(10056):2115-27. Abstract
146. FitzGerald JM, Bleecker ER, Nair P, et al; CALIMA Study Investigators. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016 Oct 29;388(10056):2128-41. Abstract
147. Nair P, Wenzel S, Rabe KF, et al; ZONDA Trial Investigators. Oral glucocorticoid-sparing effect of benralizumab in severe asthma. N Engl J Med. 2017 Jun 22;376(25):2448-58.Full text Abstract
148. Harrison TW, Chanez P, Menzella F, et al. Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial. Lancet Respir Med. 2021 Mar;9(3):260-74. Abstract
149. Menzies-Gow A, Gurnell M, Heaney LG, et al. Oral corticosteroid elimination via a personalised reduction algorithm in adults with severe, eosinophilic asthma treated with benralizumab (PONENTE): a multicentre, open-label, single-arm study. Lancet Respir Med. 2022 Jan;10(1):47-58.Full text Abstract
150. Wechsler ME, Ford LB, Maspero JF, et al. Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study. Lancet Respir Med. 2022 Jan;10(1):11-25. Abstract
151. Gallagher A, Edwards M, Nair P, et al. Anti-interleukin-13 and anti-interleukin-4 agents versus placebo, anti-interleukin-5 or anti-immunoglobulin-E agents, for people with asthma. Cochrane Database Syst Rev. 2021 Oct 19;10:CD012929.Full text Abstract
152. Corren J, Parnes JR, Wang L, et al. Tezepelumab in adults with uncontrolled asthma. N Engl J Med. 2017 Sep 7;377(10):936-46.Full text Abstract
153. Chan R, Stewart K, Misirovs R, et al. Targeting downstream type 2 cytokines or upstream epithelial alarmins for severe asthma. J Allergy Clin Immunol Pract. 2022 Feb 5 [Epub ahead of print].Full text Abstract
154. Asthma and Lung UK. Biologic therapies for severe asthma. Dec 2021 [internet publication].Full text
155. Jackson DJ, Heaney LG, Humbert M, et al. Reduction of daily maintenance inhaled corticosteroids in patients with severe eosinophilic asthma treated with benralizumab (SHAMAL): a randomised, multicentre, open-label, phase 4 study. Lancet. 2024 Jan 20;403(10423):271-81.Full text Abstract
156. Haldar P, Brightling CE, Singapuri A, et al. Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: a 12-month follow-up analysis. J Allergy Clin Immunol. 2014 Mar;133(3):921-3. Abstract
157. Ledford D, Busse W, Trzaskoma B, et al. A randomized multicenter study evaluating Xolair persistence of response after long-term therapy. J Allergy Clin Immunol. 2017 Jul;140(1):162-9.e2. Abstract
158. Moore WC, Kornmann O, Humbert M, et al. Stopping versus continuing long-term mepolizumab treatment in severe eosinophilic asthma (COMET study). Eur Respir J. 2022 Jan;59(1):2100396. Abstract
159. Korn S, Bourdin A, Chupp G, et al. Integrated safety and efficacy among patients receiving benralizumab for up to 5 years. J Allergy Clin Immunol Pract. 2021 Dec;9(12):4381-92.e4. Abstract
160. Khatri S, Moore W, Gibson PG, et al. Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma. J Allergy Clin Immunol. 2019 May;143(5):1742-51.e7. Abstract
161. Castro M, Rubin AS, Laviolette M, et al. Effectiveness and safety of bronchial thermoplasty in the treatment of severe asthma: a multicenter, randomized, double-blind, sham-controlled clinical trial. Am J Respir Crit Care Med. 2010 Jan 15;181(2):116-24.Full text Abstract
162. Wahidi MM, Kraft M. Bronchial thermoplasty for severe asthma. Am J Respir Crit Care Med. 2012 Apr 1;185(7):709-14.Full text Abstract
163. Torrego A, Solà I, Munoz AM, et al. Bronchial thermoplasty for moderate or severe persistent asthma in adults. Cochrane Database Syst Rev. 2014 Mar 3;(3):CD009910.Full text Abstract
164. Chaudhuri R, Rubin A, Sumino K, et al. Safety and effectiveness of bronchial thermoplasty after 10 years in patients with persistent asthma (BT10+): a follow-up of three randomised controlled trials. Lancet Respir Med. 2021 May;9(5):457-66. Abstract
165. Welsh EJ, Cates CJ. Formoterol versus short-acting beta-agonists as relief medication for adults and children with asthma. Cochrane Database Syst Rev. 2010 Sep 8;(9):CD008418.Full text Abstract
166. Rodrigo GJ, Neffen H, Castro-Rodriguez JA. Efficacy and safety of subcutaneous omalizumab vs placebo as add-on therapy to corticosteroids for children and adults with asthma: a systematic review. Chest. 2011 Jan;139(1):28-35.Full text Abstract
167. Corren J, Lemanske RF, Hanania NA, et al. Lebrikizumab treatment in adults with asthma. N Engl J Med. 2011 Sep 22;365(12):1088-98.Full text Abstract
168. Hanania NA, Noonan M, Corren J, et al. Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies. Thorax. 2015 Aug;70(8):748-56.Full text Abstract
169. Hanania NA, Korenblat P, Chapman KR, et al. Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials. Lancet Respir Med. 2016 Oct;4(10):781-96. Abstract
170. Korenblat P, Sher E, Berman G, et al. P069 effect of lebrikizumab on lung function in patients with severe eosinophilic asthma. Ann Allergy Asthma Immunol. 2021 Nov 1;127(5):S34.Full text
171. Szefler SJ, Roberts G, Rubin AS, et al. Efficacy, safety, and tolerability of lebrikizumab in adolescent patients with uncontrolled asthma (ACOUSTICS). Clin Transl Allergy. 2022 Jul;12(7):e12176.Full text Abstract
172. Kosloski MP, Kalliolias GD, Xu CR, et al. Pharmacokinetics and pharmacodynamics of itepekimab in healthy adults and patients with asthma: Phase I first-in-human and first-in-patient trials. Clin Transl Sci. 2022 Feb;15(2):384-95.Full text Abstract
173. Wechsler ME, Ruddy MK, Pavord ID, et al. Efficacy and safety of itepekimab in patients with moderate-to-severe asthma. N Engl J Med. 2021 Oct 28;385(18):1656-68.Full text Abstract
174. Rabe KF, Celli BR, Wechsler ME, et al. Safety and efficacy of itepekimab in patients with moderate-to-severe COPD: a genetic association study and randomised, double-blind, phase 2a trial. Lancet Respir Med. 2021 Nov;9(11):1288-98. Abstract
175. Chen Z, Peng C, Mei J, et al. Vitamin D can safely reduce asthma exacerbations among corticosteroid-using children and adults with asthma: a systematic review and meta-analysis of randomized controlled trials. Nutr Res. 2021 Aug;92:49-61. Abstract
176. Andújar-Espinosa R, Salinero-González L, Illán-Gómez F, et al. Effect of vitamin D supplementation on asthma control in patients with vitamin D deficiency: the ACVID randomised clinical trial. Thorax. 2021 Feb;76(2):126-33.Full text Abstract
177. Martineau AR, Cates CJ, Urashima M, et al. Vitamin D for the management of asthma. Cochrane Database Syst Rev. 2016 Sep 5;(9):CD011511.Full text Abstract
178. Jolliffe DA, Greenberg L, Hooper RL, et al. Vitamin D supplementation to prevent asthma exacerbations: a systematic review and meta-analysis of individual participant data. Lancet Respir Med. 2017 Nov;5(11):881-90.Full text Abstract
179. Litonjua AA, Carey VJ, Laranjo N, et al. Six-year follow-up of a trial of antenatal vitamin D for asthma reduction. N Engl J Med. 2020 Feb 6;382(6):525-33.Full text Abstract
180. Forno E, Bacharier LB, Phipatanakul W, et al. Effect of vitamin D3 supplementation on severe asthma exacerbations in children with asthma and low vitamin D levels: the VDKA randomized clinical trial. JAMA. 2020 Aug 25;324(8):752-60.Full text Abstract
181. Gurgel RK, Baroody FM, Damask CC, et al. Clinical practice guideline: immunotherapy for inhalant allergy. Otolaryngol Head Neck Surg. 2024 Mar;170(suppl 1):S1-42. Abstract
182. Toward Optimized Practice (Alberta Doctors). Chronic asthma. April 2018 [internet publication].Full text
183. Agache I, Akdis CA, Akdis M, et al. EAACI biologicals guidelines: recommendations for severe asthma. Allergy. 2021 Jan;76(1):14-44.Full text Abstract
184. Holguin F, Cardet JC, Chung KF, et al. Management of severe asthma: a European Respiratory Society/American Thoracic Society guideline. Eur Respir J. 2020 Jan 2;55(1):1900588.Full text Abstract
185. Agache I, Lau S, Akdis CA, et al. EAACI guidelines on allergen immunotherapy: house dust mite-driven allergic asthma. Allergy. 2019 May;74(5):855-73.Full text Abstract
186. Smith D, Du Rand I, Addy CL, et al. British Thoracic Society guideline for the use of long-term macrolides in adults with respiratory disease. Thorax. 2020 May;75(5):370-404.Full text Abstract
187. Sears MR, Greene JM, Willan AR, et al. A longitudinal, population-based, cohort study of childhood asthma followed to adulthood. N Engl J Med. 2003 Oct 9;349(15):1414-22.Full text Abstract
188. Phelan PD, Robertson CF, Olinksy A. The Melbourne Asthma Study: 1964-1999. J Allergy Clin Immunol. 2002 Feb;109(2):189-94. Abstract
189. James AL, Palmer LJ, Kicic E, et al. Decline in lung function in the Busselton Health Study: the effects of asthma and cigarette smoking. Am J Respir Crit Care Med. 2005 Jan 15;171(2):109-14.Full text Abstract
190. James AL, Wenzel S. Clinical relevance of airway remodelling in airway diseases. Eur Respir J. 2007 Jul;30(1):134-55.Full text Abstract
191. Bai TR, Vonk JM, Postma DS, et al. Severe exacerbations predict excess lung function decline in asthma. Eur Respir J. 2007 Sep;30(3):452-6.Full text Abstract
192. Tupper OD, Andersen ZJ, Ulrik CS. Demographic, lifestyle and comorbid risk factors for all-cause mortality in a Danish cohort of middle-aged adults with incident asthma. BMJ Open. 2021 Oct 4;11(10):e049243.Full text Abstract
193. Lommatzsch M, Buhl R, Canonica GW, et al. Pioneering a paradigm shift in asthma management: remission as a treatment goal. Lancet Respir Med. 2024 Feb;12(2):96-9. Abstract
194. Blaiss M, Oppenheimer J, Corbett M, et al. Consensus of an American College of Allergy, Asthma, and Immunology, American Academy of Allergy, Asthma, and Immunology, and American Thoracic Society workgroup on definition of clinical remission in asthma on treatment. Ann Allergy Asthma Immunol. 2023 Dec;131(6):782-5. Abstract
195. Tan DJ, Bui DS, Dai X, et al. Does the use of inhaled corticosteroids in asthma benefit lung function in the long-term? A systematic review and meta-analysis. Eur Respir Rev. 2021 Mar 31;30(159):200185.Full text Abstract
196. Slade DJ, Kraft M. Airway remodeling from bench to bedside: current perspectives. Clin Chest Med. 2006 Mar;27(1):71-85. Abstract
197. Mascia K, Haselkorn T, Deniz YM, et al. Aspirin sensitivity and severity of asthma: evidence for irreversible airway obstruction in patients with severe or difficult-to-treat asthma. J Allergy Clin Immunol. 2005 Nov;116(5):970-5. Abstract
198. Chalitsios CV, Shaw DE, McKeever TM. Risk of osteoporosis and fragility fractures in asthma due to oral and inhaled corticosteroids: two population-based nested case-control studies. Thorax. 2021 Jan;76(1):21-8.Full text Abstract
199. Price DB, Trudo F, Voorham J, et al. Adverse outcomes from initiation of systemic corticosteroids for asthma: long-term observational study. J Asthma Allergy. 2018;11:193-204. Abstract
200. Nelsen LM, Kosinski M, Rizio AA, et al. A structured review evaluating content validity of the Asthma Control Test, and its consistency with U.S. guidelines and patient expectations for asthma control. J Asthma. 2022 Mar;59(3):628-37. Abstract
201. Chu F, Kappel N, Akel M, et al. Validity of the childhood asthma control test in diverse populations: a systematic review. Pediatr Pulmonol. 2023 May;58(5):1322-36. Abstract
202. Ten Have P, van Hal P, Wichers I, et al. Turning green: the impact of changing to more eco-friendly respiratory healthcare - a carbon and cost analysis of Dutch prescription data. BMJ Open. 2022 Jun 14;12(6):e055546. Abstract
203. Riley IL, Jackson B, Crabtree D, et al. A scoping review of international barriers to asthma medication adherence mapped to the theoretical domains framework. J Allergy Clin Immunol Pract. 2021 Jan;9(1):410-8.e4. Abstract
204. van de Hei SJ, Dierick BJH, Aarts JEP, et al. Personalized medication adherence management in asthma and chronic obstructive pulmonary disease: a review of effective interventions and development of a practical adherence toolkit. J Allergy Clin Immunol Pract. 2021 Nov;9(11):3979-94.Full text Abstract
205. Murphy J, McSharry J, Hynes L, et al. Prevalence and predictors of adherence to inhaled corticosteroids in young adults (15-30 years) with asthma: a systematic review and meta-analysis. J Asthma. 2021 May;58(5):683-705. Abstract
206. Chongmelaxme B, Lee S, Dhippayom T, et al. The effects of telemedicine on asthma control and patients' quality of life in adults: a systematic review and meta-analysis. J Allergy Clin Immunol Pract. 2019 Jan;7(1):199-216. Abstract
207. Jeminiwa R, Hohmann L, Qian J, et al. Impact of eHealth on medication adherence among patients with asthma: a systematic review and meta-analysis. Respir Med. 2019 Mar;149:59-68.Full text Abstract
208. Unni E, Gabriel S, Ariely R. A review of the use and effectiveness of digital health technologies in patients with asthma. Ann Allergy Asthma Immunol. 2018 Dec;121(6):680-91.Full text Abstract
209. Mes MA, Katzer CB, Chan AHY, et al. Pharmacists and medication adherence in asthma: a systematic review and meta-analysis. Eur Respir J. 2018 Aug 23;52(2):1800485.Full text Abstract
210. Jia X, Zhou S, Luo D, et al. Effect of pharmacist-led interventions on medication adherence and inhalation technique in adult patients with asthma or COPD: A systematic review and meta-analysis. J Clin Pharm Ther. 2020 Oct;45(5):904-17.Full text Abstract
211. Muneswarao J, Hassali MA, Ibrahim B, et al. Effectiveness of home visits in adult patients with asthma: a systematic review of randomized controlled trials. J Allergy Clin Immunol Pract. 2020 Oct;8(9):3036-55. Abstract
212. Zhang Y, Cheng J, Li Y, et al. Suicidality among patients with asthma: a systematic review and meta-analysis. J Affect Disord. 2019 Sep 1;256:594-603. Abstract
213. Centers for Disease Control and Prevention. Adult immunization schedule by age (addendum updated February 29, 2024): recommendations for ages 19 years or older, United States, 2024. 2024 [internet publication].Full text
214. Cates CJ, Rowe BH. Vaccines for preventing influenza in people with asthma. Cochrane Database Syst Rev. 2013 Feb 28;2013(2):CD000364. Abstract
215. Kobayashi M, Pilishvili T, Farrar JL, et al. Pneumococcal vaccine for adults aged ≥19 years: recommendations of the Advisory Committee on Immunization Practices, United States, 2023. MMWR Recomm Rep. 2023 Sep 8;72(3):1-39. Abstract
216. Melgar M, Britton A, Roper LE, et al. Use of respiratory syncytial virus vaccines in older adults: recommendations of the Advisory Committee on Immunization Practices - United States, 2023. MMWR Morb Mortal Wkly Rep. 2023 Jul 21;72(29):793-801. Abstract
217. Osadnik CR, Gleeson C, McDonald VM, et al. Pulmonary rehabilitation versus usual care for adults with asthma. Cochrane Database Syst Rev. 2022 Aug 22;8(8):CD013485.Full text Abstract
218. Fortescue R, Kew KM, Leung MST. Sublingual immunotherapy for asthma. Cochrane Database Syst Rev. 2020 Sep 14;(9):CD011293.Full text Abstract
219. Kappen J, Diamant Z, Agache I, et al. Standardization of clinical outcomes used in allergen immunotherapy in allergic asthma: an EAACI position paper. Allergy. 2023 Nov;78(11):2835-50.Full text Abstract
220. Nyenhuis SM, Kahwash B, Cooke A, et al. Recommendations for physical activity in asthma: a work group report of the AAAAI Sports, Exercise, and Fitness Committee. J Allergy Clin Immunol Pract. 2022 Feb;10(2):433-43. Abstract
221. Kahwash BM, Gregory KL, Sharp LK, et al. Results from a national survey of asthma provider beliefs and practices regarding exercise and asthma: a work group report of the AAAAI Committee on Sports, Exercise, and Fitness. J Allergy Clin Immunol Pract. 2022 Jul;10(7):1778-83.Full text Abstract
222. McLoughlin RF, Clark VL, Urroz PD, et al. Increasing physical activity in severe asthma: a systematic review and meta-analysis. Eur Respir J. 2022 Dec;60(6):2200546. Abstract
223. Valkenborghs SR, Anderson SL, Scott HA, et al. Exercise training programs improve cardiorespiratory and functional fitness in adults with asthma: a systemic review and meta-analysis. J Cardiopulm Rehabil Prev. 2022 Nov 1;42(6):423-33. Abstract
224. Quirce S, Domínguez-Ortega J, Luna JA. Novel approaches in occupational asthma diagnosis and management. Curr Opin Pulm Med. 2021 Jan;27(1):9-14.Full text Abstract
225. Leas BF, D'Anci KE, Apter AJ, et al. Effectiveness of indoor allergen reduction in asthma management: a systematic review. J Allergy Clin Immunol. 2018 May;141(5):1854-69.Full text Abstract
226. Okoniewski W, Lu KD, Forno E. Weight loss for children and adults with obesity and asthma: a systematic review of randomized controlled trials. Ann Am Thorac Soc. 2019 May;16(5):613-25.Full text Abstract
227. Thompson CA, Eslick SR, Berthon BS, et al. Asthma medication use in obese and healthy weight asthma: systematic review/meta-analysis. Eur Respir J. 2021 Mar;57(3):2000612.Full text Abstract
228. Hossain N, Arhi C, Borg CM. Is bariatric surgery better than nonsurgical weight loss for improving asthma control? A Systematic Review. Obes Surg. 2021 Apr;31(4):1810-32. Abstract
229. Santino TA, Chaves GS, Freitas DA, et al. Breathing exercises for adults with asthma. Cochrane Database Syst Rev. 2020 Mar 25;(3):CD001277.Full text Abstract
230. Lee C, Alexander E, Lee R, et al. Behavioral interventions for asthma self-management in South Asian populations: a systematic review. J Asthma. 2021 Jan;58(1):112-20. Abstract
Use of this content is subject to our disclaimer